ABIONYX Pharma Triples Yield on Key Component of Its Sepsis Treatment
ABIONYX Pharma announces the development of a new manufacturing process for synthetic sphingomyelin, a key component of its CER-001 product for sepsis treatment. This breakthrough aims to secure bioproduction on an industrial scale and upcoming regulatory steps.
The biopharmaceutical company has developed a new process that triples the production yield of sphingomyelin, one of the two major components of CER-001. This synthetic sphingomyelin is characterized by exceptional purity and structural quality that meets the most stringent pharmaceutical standards. The synthesis processes are based on patents fully owned by ABIONYX Pharma, creating a significant technological and competitive barrier. The use of 100% synthetic sphingomyelin instead of traditional sources (egg or bovine) eliminates any risk of contamination, variability in raw materials, and allergic risks.
Enhanced Stabilization and Therapeutic Capabilities
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
In the biomedicine CER-001, sphingomyelin stabilizes the apoA-I protein in an optimally functional conformation and enhances the product's biological and therapeutic capabilities. This advancement will directly benefit the manufacturing of the two validation batches required before the Market Authorization in LCAT deficiency, ensuring high purity, optimal reproducibility, and secured supply. ABIONYX Pharma positions this success as a validation of its industrial approach to the apoA-I platform and the preparation for clinical and regulatory stages. The company also highlights that mastering synthetic sphingomyelin could open other commercial opportunities, especially in advanced cosmetics, where this component is used for its abilities to stabilize and protect biological structures.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 1,9 millions d'euros
Quarterly revenue: 1,9 millions d'euros
Net income: -4,8 millions d'euros
-11,7 millions d'euros
Guidance from the release
« Le Groupe ayant réalisé en juin une opération de financement par augmentation de capital et dette obligataire simple (détaillé en Note O. « Dettes financières »), elle dispose d'une trésorerie suffisante pour faire face à ses besoins de trésorerie pendant au moins douze mois à compter de la date d'arrêté des comptes. »
Risks mentioned
Absence de revenu généré par l'activité biotech principale au T2 2026
Bioproduit fourni gratuitement dans le cadre des autorisations d'accès compassionnel, sans revenu associé
Dépendance du chiffre d'affaires consolidé à la seule filiale IRIS Pharma
Opportunities identified
Trésorerie de 26,9 M€ suite à l'opération de financement annoncée le 18 juin 2026
Visibilité financière étendue jusqu'à fin 2028
Chiffre d'affaires d'IRIS Pharma anticipé stable pour l'exercice 2026 par rapport à 2025
Outlook / guidance
Management commentary: « Based on the information available as of the date of this press release, the Company anticipates that IRIS Pharma's revenue for fiscal year 2026 will remain broadly stable compared to that of fiscal year 2025. »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
